CJC-1295 and Ipamorelin Blend Documentation in Secretagogue Research

CJC-1295 and Ipamorelin are complementary growth hormone (GH) secretagogues studied in laboratory research. CJC-1295 is a long-acting synthetic analog of GH-releasing hormone (GHRH) that binds serum albumin to extend its half-life, while Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist pentapeptide【10†L169-L177】【43†L197-L204】. These peptides are provided as research-use-only materials (RUO) for preclinical studies of the somatotropic axis, not for human or animal use. Documentation (e.g. batch-specific Certificates of Analysis) is critical to verify purity, identity, and labeling for laboratory protocols.

Fast Answer

Background on CJC-1295 and Ipamorelin

CJC-1295 (no-DAC) and Ipamorelin are laboratory-grade peptides that stimulate GH release by different mechanisms. CJC-1295 is a modified GHRH analog (30 amino acids) engineered to bind endogenous albumin after injection【10†L169-L177】, resulting in a prolonged half-life (on the order of days) and extended GH/IGF-1 elevation【10†L169-L177】【24†L130-L138】. Ipamorelin (NNC 26-0161) is a synthetic five-residue peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the ghrelin/GHS-R1a receptor on pituitary cells【43†L174-L182】【43†L197-L204】. Notably, Ipamorelin potently elicits GH release with negligible stimulation of ACTH or cortisol【43†L197-L204】, distinguishing it from earlier secretagogues. Both peptides are supplied at high analytical purity (typically ≥95–99% HPLC) as lyophilized powders, with sequence and CAS details provided on the COA. They are labeled “For Laboratory Research Use Only, Not for Human or Animal Use,” reflecting RUO compliance standards.

Mechanisms of Action in the Growth Hormone Axis

In GH-secretagogue research, CJC-1295 and Ipamorelin target different receptors to synergistically stimulate GH secretion. CJC-1295 mimics endogenous GHRH by binding the GHRH receptor on pituitary somatotrophs and raising intracellular cAMP, leading to sustained GH mRNA and hormone release【10†L179-L182】【24†L130-L138】. Ipamorelin binds the ghrelin receptor (GHS-R1a) on the pituitary, triggering a rapid but transient GH pulse. In human PK/PD studies, Ipamorelin infusion caused a single GH peak about 0.7 hours after dosing, with a short ~2-hour peptide half-life【31†L69-L74】. Combined, CJC-1295 amplifies overall GH exposure over days while Ipamorelin produces discrete GH surges. These pathways ultimately converge on hepatic IGF-1 production, as elevated GH drives IGF-1 release (Figure 1). Researchers use this dual approach to probe somatotroph regulation and downstream metabolic effects.

Figure 1: Flowchart of the growth hormone (GH) secretagogue pathways for CJC-1295 and Ipamorelin in research. CJC-1295 (GHRH analog) binds the GHRH receptor on pituitary somatotrophs, while Ipamorelin binds the ghrelin (GHS-R1a) receptor. Both signals converge to activate somatotroph cells and stimulate GH release, which in turn increases IGF-1 production in the liver.

Research Applications of the Peptide Blend

Laboratories employ the CJC-1295 + Ipamorelin combination to study GH dynamics, metabolic regulation, and related pathways. For example, in GHRH-deficient mouse models, daily CJC-1295 injections restored normal growth and body composition, increasing pituitary GH mRNA as somatotrophs proliferated【10†L179-L182】. In healthy adult volunteers, single doses of CJC-1295 produced 2–10× increases in mean plasma GH lasting 6+ days, and corresponding 1.5–3× elevations in IGF‑1 for over a week【24†L130-L138】. Ipamorelin trials in humans demonstrate a sharp GH pulse with each dose (peak ~0.7 h, decline to baseline by ~2 h)【31†L69-L74】. The blend is also used in preclinical models; for instance, GHSR agonists like Ipamorelin (often with GHRPs) were found to enhance bone formation in adult rats, indicating potential utility for skeletal research. The table below summarizes select findings from peer-reviewed studies:

Quality Documentation and Analytical Testing

Ensuring accuracy and consistency requires thorough documentation for every RUO peptide lot. Suppliers should provide a batch-specific Certificate of Analysis (COA) detailing the compound’s identity and purity. Key QC data include reversed-phase HPLC chromatograms (demonstrating a single main peak) and mass spectrometry confirming the expected molecular weight. For example, a valid COA for CJC-1295/Ipamorelin will list the peptide sequences, CAS numbers, net peptide content, water content, and purity (typically ≥95–99%)【31†L69-L74】【43†L197-L204】. Additional parameters may include residual solvent and endotoxin levels (if applicable). All labeling must clearly state “For Research Use Only” and exclude any claims of therapeutic benefit. Laboratories should review this documentation before using peptides in experiments and retain COAs for data traceability.

FAQs

What roles do CJC-1295 and Ipamorelin serve in research?

CJC-1295 and Ipamorelin are laboratory research peptides used to study growth hormone regulation. Researchers use CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin/GHS-R agonist) together to stimulate the pituitary somatotroph cells via two pathways【10†L169-L177】【43†L197-L204】. The aim is to examine GH release and downstream effects (like IGF-1 production) under controlled, preclinical conditions. These compounds are strictly RUO materials; they support in vitro and animal studies of endocrine mechanisms and metabolism, not clinical or consumer use.

How do CJC-1295 and Ipamorelin differ mechanistically?

CJC-1295 and Ipamorelin act on different receptors in the GH axis. CJC-1295 binds the GH-releasing hormone (GHRH) receptor on pituitary cells, raising intracellular cAMP for sustained GH release【10†L169-L177】. Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a, also called the ghrelin receptor) on the pituitary, triggering a brief, pulsatile GH surge【31†L69-L74】【43†L174-L182】. Together, they can provide both continuous and pulse-like GH stimulation in research models. Neither peptide directly administers GH; instead, they provoke the body’s endogenous GH production.

What quality tests are performed on these peptide blends?

Each batch of CJC-1295/Ipamorelin should undergo analytical testing to verify its identity and purity. High-performance liquid chromatography (HPLC) is used to measure purity (ideally showing ≥95–99% of the main peptide peak). Mass spectrometry (often MALDI or ESI-MS) confirms the exact molecular weight matches the theoretical peptide【31†L69-L74】. Certificates of Analysis typically include these results along with residual water content and any contaminants. Researchers should consult the COA to ensure the product meets required specifications before experimentation.

What information is on a peptide Certificate of Analysis?

A peptide COA provides batch-specific data for researchers. It typically lists the peptide name, sequence, and CAS number, followed by measured values: net weight, water content, purity (HPLC), and identity confirmation (MS)【31†L69-L74】. Some COAs also report purity percentage, retention time, chromatogram, and analytical method details. For RUO peptides, the COA will clearly state “For Research Use Only” with no clinical claims. Users should verify that the COA matches the ordered peptide and meets their purity requirements.

What does “research-use-only” mean for peptides?

“Research Use Only” (RUO) indicates that peptides like CJC-1295 and Ipamorelin are intended solely for laboratory and preclinical studies, not for any diagnostic, therapeutic, or personal use. RUO labeling means the product is not approved for clinical or veterinary purposes. Suppliers must exclude any efficacy or safety claims on the label【10†L169-L177】【43†L197-L204】. In practice, RUO peptides come with detailed documentation (COAs, SDS, etc.) and require users to comply with local regulations on research chemicals. The focus is on data reproducibility and safety in controlled experimental settings.

Next Steps

Always review batch-specific COAs and documentation before working with any RUO peptides. When selecting secretagogues like CJC-1295/Ipamorelin, prioritize suppliers that provide transparent labeling and complete analytical data. Explore Pure Lab Peptides for laboratory-grade peptide blends; their products include clear RUO notices, detailed COAs, and research-focused support to ensure compliance and quality in GH secretagogue studies.

References

1. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” American Journal of Physiology – Endocrinology and Metabolism. 2006;291(6):E1290–E1294. doi.org/10.1152/ajpendo.00201.2006
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. doi.org/10.1210/jc.2005-1536
3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharmaceutical Research. 1999;16(9):1412–1416. doi.org/10.1023/A:1018955126402
4. Raun K, Sehested-Hansen B, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. doi.org/10.1530/eje.0.1390552